Literature DB >> 15994457

Discovery and therapeutic promise of selective androgen receptor modulators.

Jiyun Chen1, Juhyun Kim, James T Dalton.   

Abstract

Androgens are essential for male development and the maintenance of male secondary characteristics, such as bone mass, muscle mass, body composition, and spermatogenesis. The main disadvantages of steroidal androgens are their undesirable physicochemical and pharmacokinetic properties. The recent discovery of nonsteroidal selective androgen receptor modulators (SARMs) provides a promising alternative for testosterone replacement therapies with advantages including oral bioavailability, flexibility of structural modification, androgen receptor specificity, tissue selectivity, and the lack of steroid-related side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994457      PMCID: PMC2072877          DOI: 10.1124/mi.5.3.7

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  86 in total

1.  The effect of finasteride in men with benign prostatic hyperplasia. 1992.

Authors:  Gleen J Gormley; Elizabeth Stoner; Reginald C Bruskewitz; Julianne Imperato-McGinley; Patrick C Walsh; John D McConnell; Gerald L Andriole; Jack Geller; Bruce R Bracken; Joyce S Tenover; E Darracott Vaughan; Frances Pappas; Alice Taylor; Bruce Binkowitz; Jennifer Ng
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

Review 2.  Progress towards hormonal male contraception.

Authors:  Axel Kamischke; Eberhard Nieschlag
Journal:  Trends Pharmacol Sci       Date:  2004-01       Impact factor: 14.819

Review 3.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

4.  Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.

Authors:  Donghua Yin; Yali He; Minoli A Perera; Seoung Soo Hong; Craig Marhefka; Nina Stourman; Leonid Kirkovsky; Duane D Miller; James T Dalton
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

5.  A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men.

Authors:  W M Hair; K Kitteridge; D B O'Connor; F C Wu
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

6.  Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.

Authors:  H M Behre; S Baus; S Kliesch; C Keck; M Simoni; E Nieschlag
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

7.  Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats.

Authors:  R T Turner; G K Wakley; K S Hannon
Journal:  J Orthop Res       Date:  1990-07       Impact factor: 3.494

8.  A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

Authors:  Yi-Qun Gu; Xing-Hai Wang; Dwo Xu; Lin Peng; Li-Fa Cheng; Ming-Kong Huang; Zhen-Jia Huang; Gui-Yuan Zhang
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

9.  Effect of chronic administration of 7alpha-methyl-19-nortestosterone on serum testosterone, number of spermatozoa and fertility in adult male bonnet monkeys (Macaca radiata).

Authors:  S G Ramachandra; V Ramesh; H N Krishnamurthy; N Kumar; K Sundaram; M P Hardy; A Jagannadha Rao
Journal:  Reproduction       Date:  2002-08       Impact factor: 3.906

10.  A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men.

Authors:  Sigrid von Eckardstein; Gabriela Noe; Vivian Brache; Eberhard Nieschlag; Horacio Croxatto; Francisco Alvarez; Alfred Moo-Young; Irving Sivin; Narender Kumar; Margaret Small; Kalyan Sundaram
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

View more
  16 in total

1.  Alanine aminotransferase regulation by androgens in non-hepatic tissues.

Authors:  Christopher C Coss; Matt Bauler; Ramesh Narayanan; Duane D Miller; James T Dalton
Journal:  Pharm Res       Date:  2011-12-14       Impact factor: 4.200

Review 2.  Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.

Authors:  Zachary J Solomon; Jorge Rivera Mirabal; Daniel J Mazur; Taylor P Kohn; Larry I Lipshultz; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2018-11-30

Review 3.  Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?

Authors:  Wenqing Gao; James T Dalton
Journal:  Mol Interv       Date:  2007-02

Review 4.  The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications.

Authors:  Amy B Cadwallader; Carol S Lim; Douglas E Rollins; Francesco Botrè
Journal:  J Anal Toxicol       Date:  2011-11       Impact factor: 3.367

5.  Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions.

Authors:  Chun-Song Yang; Hong-Wu Xin; Joshua B Kelley; Adam Spencer; David L Brautigan; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

Review 6.  Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).

Authors:  Wenqing Gao; James T Dalton
Journal:  Drug Discov Today       Date:  2007-02-07       Impact factor: 7.851

Review 7.  Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands.

Authors:  Wenqing Gao; Juhyun Kim; James T Dalton
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

8.  Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus.

Authors:  Alicia M Blessing; Sathya Ganesan; Kimal Rajapakshe; Ying Ying Sung; Lakshmi Reddy Bollu; Yan Shi; Edwin Cheung; Cristian Coarfa; Jeffrey T Chang; Donald P McDonnell; Daniel E Frigo
Journal:  Mol Endocrinol       Date:  2015-08-25

9.  Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception.

Authors:  Amanda Jones; Jiyun Chen; Dong Jin Hwang; Duane D Miller; James T Dalton
Journal:  Endocrinology       Date:  2008-09-04       Impact factor: 4.736

Review 10.  Sex hormones, their receptors and bone health.

Authors:  K Venken; F Callewaert; S Boonen; D Vanderschueren
Journal:  Osteoporos Int       Date:  2008-04-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.